An astaxanthin dosage on a finished label is the active milligrams per serving. A research dose, a commercial serving, and a permitted serving can share a number and still be three different decisions. An astaxanthin supplement manufacturer checks whether the chosen serving fits the ingredient and the dosage form. This guide is for brand and formulation teams. It is not personal dosage advice.
Active Milligrams Are Not Preparation Weight
A 12 mg serving does not mean the softgel contains 12 mg of material. Commercial inputs are standardized preparations. At 5%, one gram of preparation contains about 50 mg of active astaxanthin. The rest is carrier oil, algal residue, beadlet solids, or other excipients.
Required preparation mass = target active astaxanthin ÷ concentration.
The table is theoretical preparation weight. It is not the finished fill weight, and it is not a manufacturing batch instruction. Use the lot assay, and use the same definition of “active” that the label will declare.
Active astaxanthin per serving | 2% preparation | 5% preparation | 10% preparation |
|---|---|---|---|
| 4 mg | 200 mg | 80 mg | 40 mg |
| 6 mg | 300 mg | 120 mg | 60 mg |
| 8 mg | 400 mg | 160 mg | 80 mg |
| 12 mg | 600 mg | 240 mg | 120 mg |
| 24 mg | 1,200 mg | 480 mg | 240 mg |
A percent on a sales sheet converts to a batch weight only when the assay basis matches the label. Confirm whether the result is free astaxanthin, ester equivalents, or total astaxanthin; whether it is on an as-is or dry basis; the lot result and its specification range; and whether the finished-product method can support the declared amount. A nominal 5% or 10% is not that check.
A 5% powder and a 5% oil share the arithmetic and not the fill. The powder occupies capsule volume as a dry solid. The oil is a liquid suspension. Powder grades also include 1% and 2.5%. Divide the target milligrams by the tested percent the same way.
At 10% oil, 12 mg of active astaxanthin is about 120 mg of preparation. At 2% powder, the same claim is about 600 mg. The second figure may exceed the practical fill capacity of a single unit. Capsule size is not the assay.
Choose a Serving from the Specification and the Evidence
The amounts below are specification examples, not a recommended dose ladder. A dose used in a human study shows only what that study tested. A commercial serving is an amount printed on a label. A permitted serving is the amount allowed for that ingredient identity, population, and product category in the destination market. The three can overlap. They are not synonyms. A higher dose does not imply a proportionally greater effect.
Named US finished-product labels checked on 12 October 2026 included 4 mg, 6 mg, 12 mg, and 24 mg servings. Gummy examples in that check were about 4–6 mg per serving. The check is a set of examples, not a census of the market.
Amount | What was tested or observed | What it does not authorize |
|---|---|---|
| 4 mg | A small skin trial used 4 mg/day [1] | A high-potency claim, or a sunscreen claim |
| 6 mg | A screen-use trial used 6 mg with lutein and zeaxanthin [3] | Credit for astaxanthin alone |
| 8 mg | EFSA assessed an adult exposure scenario at 8 mg/day from supplements plus diet [4] | A universal intake, a children’s serving, or permission for a higher serving |
| 12 mg | Adult trials have used 12 mg/day [6][7] | A larger version of a 4 mg skin result, or permission in every market |
| 24 mg | One small trial in older adults used 24 mg/day inside a multi-ingredient supplement [8] | A standard next step after 12 mg, or a general wellness serving |
4 mg and 6 mg
Four milligrams is the research dose in a 9-week trial in 23 healthy Japanese adults that measured ultraviolet-induced skin changes. [1] The sample was small. It does not make 4 mg a sunscreen or a whitening dose. Several skin studies reviewed by Ng and colleagues used about 3–6 mg per day. [2] A 4 mg serving should not be described as high potency solely by comparison with lower-dose products.
Six milligrams is the astaxanthin amount in the screen-use trial, taken with 10 mg of lutein and 2 mg of zeaxanthin for eight weeks. [3] A label that cites that trial has to carry the combination. Six milligrams of astaxanthin alone is a different specification.
8 mg
EFSA’s 2020 opinion concluded that a combined exposure scenario of 8 mg/day of astaxanthin from food supplements plus estimated dietary exposure was safe for adults under the conditions assessed. [4] The conclusion belongs to that assessment. It does not set a universal recommended intake, and it does not authorize a higher serving in another market. Adolescents and younger children were a different exposure question in the same opinion. Confirm the ingredient authorization, the product category, and the permitted use level before a commercial serving is selected. A children’s gummy should not inherit the adult 8 mg figure.
An 8 mg cognitive trial used astaxanthin-rich extract from Paracoccus carotinifaciens, not from Haematococcus pluvialis. [5] An H. pluvialis specification should not cite that trial as if the materials were the same.
12 mg and 24 mg
Twelve milligrams has been a research dose in adults. A small, short crossover in trained cyclists used 12 mg per day for seven days and reported a time-trial difference. [6] A one-year trial in kidney-transplant recipients used 12 mg per day and did not show a significant benefit on its primary measures of arterial stiffness, oxidative stress, or inflammation. [7] Neither result enlarges a 4 mg skin finding, and neither is a market authorization. Where 12 mg is permitted, the label still has to say whether that amount is one unit or two.
A 24 mg/day regimen has been studied. It should not be treated as the next step in a standard dose range. A 16-week trial in nursing-home residents aged 67–94 assigned 13 people to a supplement providing 24 mg/day of astaxanthin with 40 mg of tocotrienols and 30 mg of ascorbic acid, and 11 people to the same tocotrienols and ascorbic acid without astaxanthin. [8] The study reported a difference in six-minute walking distance and in selected oxidative-stress measures, and no significant difference in muscle mass or strength. Because both arms contained tocotrienols and ascorbic acid, the between-group difference is the addition of astaxanthin on that background. It is not a test of 24 mg of astaxanthin in a plain carrier. The small study does not establish 24 mg as a general wellness serving. A 24 mg serving requires a separate, explicit review of the applicable market authorization. [4][8]
Same Milligrams Can Still Be a Different Exposure
Astaxanthin is fat-soluble. In a human pharmacokinetic comparison, lipid-based formulations produced about 1.7 to 3.7 times the exposure of the reference supplement. [9] A later crossover compared a micellar preparation with standard astaxanthin at the same 8 mg. The micellar preparation reached a higher reported peak concentration, and reached it sooner. [10]
Those papers describe the preparations tested. They do not authorize a “more bioavailable” line on a different commercial ingredient. Two labels that both say 8 mg can still differ in source organism, ester form, and carrier.
Oil, powder, and gummies change how much non-active mass travels with each milligram. In the label examples above, gummy servings were about 4–6 mg. A higher claim on a gummy usually means more pieces. The dosage form follows the serving. It does not change the active milligrams the label must declare.
Overage Is Not a Fixed Percent
The calculation below illustrates an assumed retention rate. It is not a manufacturing specification. Actual overage must be justified by product-specific stability data, analytical variability, process performance, packaging, and applicable label tolerances. Confirm that the resulting amount at release and at the end of shelf life stays inside the permitted specification for that market.
If a formula were assumed to retain 92% of its assay, a 12 mg label claim would imply a theoretical starting amount near 12 ÷ 0.92 = 13.0 mg. That illustration is not a batch instruction. Extra active on a 12 mg or 24 mg serving can move the product outside the exposure the market authorization assumed.
What to Lock Before the Label Is Printed
The specification should name:
- Active astaxanthin per unit and per serving, and whether that figure is a research dose, a commercial serving, or a permitted serving
- Source organism (H. pluvialis or another named source)
- Preparation form and tested concentration, with oil and powder distinguished at the same percent
- Assay basis: free astaxanthin, ester equivalents, or total; as-is or dry basis; the lot result and its range
- The finished-product method that will support the declared amount
- Carrier and any second active
- Unit count that delivers the serving
- Target market, ingredient authorization, and permitted use level
- Overage justified by that product’s stability data
Share the target serving, the ingredient specification, the dosage form, and the destination market when you request a formulation feasibility review.
FAQ
What astaxanthin dosage appears on finished labels? A US label check on 12 October 2026 included 4 mg, 6 mg, 12 mg, and 24 mg servings. That is a set of examples, not a recommended intake and not a market census.
Is 12 mg of astaxanthin too much? Twelve milligrams has been used in adult trials. EFSA’s 2020 opinion assessed an adult scenario of 8 mg/day from supplements plus diet. It does not authorize 12 mg in other markets. [4] Permission depends on the destination authorization.
Is 24 mg better than 12 mg? No general comparison establishes that. The 24 mg trial was a small study in older nursing-home residents, and the tested product also contained tocotrienols and ascorbic acid. [8]
Why do some 12 mg products use two capsules? The required preparation mass may exceed the practical fill capacity of a single unit. Amount per unit and amount per serving both belong on the panel.
Does astaxanthin need an oil carrier? It is fat-soluble, and lipid-based preparations showed higher exposure than a reference supplement in one human pharmacokinetic study. [9] The carrier has to be the one in the formula under review.
How much overage should the formula contain? None is set here. Justify it with that product’s stability data, analytical variability, process performance, packaging, and label tolerances.
Related
Technical and Regulatory References
- Ito N, Seki S, Ueda F. The protective role of astaxanthin for UV-induced skin deterioration in healthy people—a randomized, double-blind, placebo-controlled trial. Nutrients. 2018;10(7):817. https://doi.org/10.3390/nu10070817 · https://pubmed.ncbi.nlm.nih.gov/29941810/
- Ng QX, De Deyn MLZQ, Loke W, Foo NX, Chan HW, Yeo WS. Effects of astaxanthin supplementation on skin health: a systematic review of clinical studies. J Diet Suppl. 2021;18(2):169-182. https://doi.org/10.1080/19390211.2020.1739187 · https://pubmed.ncbi.nlm.nih.gov/32202443/
- Yoshida K, Sakai O, Honda T, Kikuya T, et al. Effects of astaxanthin, lutein, and zeaxanthin on eye–hand coordination and smooth-pursuit eye movement after visual display terminal operation in healthy subjects. Nutrients. 2023;15(6):1459. https://doi.org/10.3390/nu15061459 · https://pubmed.ncbi.nlm.nih.gov/36986186/
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of astaxanthin for its use as a novel food in food supplements. EFSA Journal. 2020;18(2):5993. https://doi.org/10.2903/j.efsa.2020.5993
- Hayashi M, Ishibashi T, Maoka T. Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on cognitive function in middle-aged and older individuals. J Clin Biochem Nutr. 2018;62(2):195-205. https://pubmed.ncbi.nlm.nih.gov/29610561/
- The effect of astaxanthin supplementation on performance and fat oxidation during a 40 km cycling time trial. PubMed PMID: 32660833. https://pubmed.ncbi.nlm.nih.gov/32660833/
- Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: the XANTHIN trial. PubMed PMID: 26675778. https://pubmed.ncbi.nlm.nih.gov/26675778/
- Impacts of astaxanthin supplementation on walking capacity by reducing oxidative stress in nursing home residents. Int J Environ Res Public Health. 2022;19(20):13492. https://pubmed.ncbi.nlm.nih.gov/36294075/
- Mercke Odeberg J, Lignell Å, Pettersson A, Höglund P. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid-based formulations. Eur J Pharm Sci. 2003;19(4):299-304. https://pubmed.ncbi.nlm.nih.gov/12885395/
- Comparative pharmacokinetic study of standard astaxanthin and its micellar formulation in healthy male volunteers. PubMed PMID: 38748358. https://pubmed.ncbi.nlm.nih.gov/38748358/
Disclaimer
For brand and formulation teams. Not personal dosage advice and not a medical recommendation. Research doses, commercial label amounts, and permitted servings are separate decisions. Study amounts are not recommended intakes. KS Nutripharma manufactures to an agreed specification and does not approve claims.
Written by the KS Nutripharma formulation team | Reviewed for serving specification, active-versus-preparation weight, and claim boundaries, not as personal dosage advice or a clinical endorsement | Updated October 12, 2026
Team background: KS Nutripharma
